Literature DB >> 15833842

Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells.

Jorge S Burns1, Basem M Abdallah, Per Guldberg, Jørgen Rygaard, Henrik D Schrøder, Moustapha Kassem.   

Abstract

Long-term cultures of telomerase-transduced adult human mesenchymal stem cells (hMSC) may evolve spontaneous genetic changes leading to tumorigenicity in immunodeficient mice (e.g., hMSC-TERT20). We wished to clarify whether this unusual phenotype reflected a rare but dominant subpopulation or if the stem cell origin allowed most cells to behave as cancer stem cells. Cultures of the hMSC-TERT20 strain at population doubling 440 were highly clonogenic (94%). From 110 single-cell clones expanded by 20 population doublings, 6 underwent detailed comparison. Like the parental population, each clone had approximately 1.2 days doubling time with loss of contact inhibition. All retained 1,25-(OH)(2) vitamin D(3)-induced expression of osteoblastic markers: collagen type I, alkaline phosphatase, and osteocalcin. All shared INK4a/ARF gene locus deletion and epigenetic silencing of the DBCCR1 tumor suppressor gene. Despite in vitro commonality, only four of six clones shared the growth kinetics and 100% tumorigenicity of the parental population. In contrast, one clone consistently formed latent tumors and the other established tumors with only 30% penetrance. Changing the in vitro microenvironment to mimic in vivo growth aspects revealed concordant clonal heterogeneity. Latent tumor growth correlated with extracellular matrix entrapment of multicellular spheroids and high procollagen type III expression. Poor tumorigenicity correlated with in vitro serum dependence and high p27(Kip1) expression. Aggressive tumorigenicity correlated with good viability plus capillary morphogenesis on serum starvation and high cyclin D1 expression. Thus, hMSC-TERT20 clones represent cancer stem cells with hierarchical tumorigenicity, providing new models to explore the stem cell hypothesis for cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833842     DOI: 10.1158/0008-5472.CAN-04-2218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Heparan sulfate enhances the self-renewal and therapeutic potential of mesenchymal stem cells from human adult bone marrow.

Authors:  Torben Helledie; Christian Dombrowski; Bina Rai; Zophia X H Lim; Ian Lee Hock Hin; David A Rider; Gary S Stein; Wanjin Hong; Andre J van Wijnen; James H Hui; Victor Nurcombe; Simon M Cool
Journal:  Stem Cells Dev       Date:  2012-01-18       Impact factor: 3.272

Review 2.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Spontaneous transformation of a clonal population of dermis-derived multipotent cells in culture.

Authors:  Chunmeng Shi; Yue Mai; Ying Zhu; Tianmin Cheng; Yongping Su
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-09-18       Impact factor: 2.416

Review 4.  The Spectrum of Fundamental Basic Science Discoveries Contributing to Organismal Aging.

Authors:  Joshua N Farr; Maria Almeida
Journal:  J Bone Miner Res       Date:  2018-08-13       Impact factor: 6.741

5.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors:  Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

Review 6.  Concise review: adult multipotent stromal cells and cancer: risk or benefit?

Authors:  Gwendal Lazennec; Christian Jorgensen
Journal:  Stem Cells       Date:  2008-04-03       Impact factor: 6.277

7.  Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Gen Suzuki; Techung Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-10-15       Impact factor: 3.575

8.  Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice.

Authors:  Raffaella Melzi; Barbara Antonioli; Alessia Mercalli; Manuela Battaglia; Andrea Valle; Stefano Pluchino; Rossella Galli; Valeria Sordi; Emanuele Bosi; Gianvito Martino; Ezio Bonifacio; Claudio Doglioni; Lorenzo Piemonti
Journal:  PLoS One       Date:  2010-04-27       Impact factor: 3.240

9.  Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors.

Authors:  Adiba Isa; Jan O Nehlin; Hardee J Sabir; Tom E Andersen; Michael Gaster; Moustapha Kassem; Torben Barington
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy.

Authors:  Morten Gjerstorff; Jorge S Burns; Ole Nielsen; Moustapha Kassem; Henrik Ditzel
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.